GlassScriptPhysician profile
Lori Leaseburge
NPI 1275628455
$2,299.73
in general payments reported to CMS, 2019-2025
34 companies · $516 in 2025
The $516 reported for 2025 was more than what 81% of Obstetrics providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $260 · 2020: $209 · 2021: $290 · 2022: $337 · 2023: $498 · 2024: $190 · 2025: $516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,203.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $304.36 | 2019-2025 | Tirosint, Tirosint, Flector |
| Astellas Pharma US INC | $180.65 | 2019-2025 | Veozah, Myrbetriq |
| Axsome Therapeutics, INC. | $174.69 | 2023-2025 | Sunosi |
| Novo Nordisk INC | $146.98 | 2021-2025 | Wegovy, Saxenda |
| Abbvie INC. | $144.68 | 2019-2025 | |
| Therapeuticsmd, INC. | $129.63 | 2019-2022 | |
| Exact Sciences Corporation | $121.89 | 2023-2025 | Cologuard Collection Kit |
| Corcept Therapeutics | $117.75 | 2021-2023 | Korlym |
| Acella Pharmaceuticals, LLC | $96.75 | 2021-2025 | NP Thyroid 60 |
| Exeltis, USA INC. | $77.51 | 2021-2025 | Slynd |
| Mayne Pharma Commercial LLC | $72.27 | 2021-2025 | |
| Endo Pharmaceuticals INC. | $67.22 | 2019-2022 | |
| Hologic Sales and Service, LLC | $65.34 | 2020-2023 | Aptima, Thinprep 2000 Processor |
| Bayer Healthcare Pharmaceuticals INC. | $62.51 | 2022-2025 | |
| Vertical Pharmaceuticals, LLC | $49.32 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acerus Pharmaceuticals Corporation | $45.73 | 2022 | |
| Daiichi Sankyo INC. | $44.13 | 2020 | |
| Millicent US INC | $40.63 | 2020-2025 | Femring, Intrarosa |
| Coloplast Corp | $35.47 | 2025 | |
| Azurity Pharmaceuticals, INC. | $35.15 | 2023 | Adthyza |
| Takeda Pharmaceuticals U.S.A., INC. | $27.35 | 2019 | |
| Ascend Therapeutics US, LLC | $26.42 | 2021 | |
| Clarus Therapeutics INC. | $25.80 | 2021 | |
| Idorsia Pharmaceuticals US INC | $25.68 | 2023 | Quviviq |
| Avion Pharmaceuticals | $25.64 | 2021-2022 | |
| Concordia Pharmaceuticals INC. | $25.08 | 2019 | |
| Evofem Biosciences, INC. | $23.16 | 2023 | Phexxi |
| Antares Pharma, INC. | $20.18 | 2025 | Xyosted |
| Sumitomo Pharma America, INC. | $17.62 | 2025 | Gemtesa |
| Duchesnay USA Incorporated | $17.07 | 2019 | |
| Vivus LLC | $15.00 | 2020 | |
| Amneal Pharmaceuticals LLC | $14.33 | 2021 | |
| Amgen INC. | $12.04 | 2022 | |
| Amag Pharmaceuticals, INC. | $11.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Leaseburge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.